Unknown

Dataset Information

0

Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.


ABSTRACT: Population pharmacokinetic (popPK) modeling was used to characterize the PK profile of the oral Janus kinase (JAK)1/JAK2 inhibitor, baricitinib, in 18 patients with Mendelian interferonopathies who are enrolled in a compassionate use program. Patients received doses between 0.1 to 17?mg per day. Covariates of weight and renal function significantly influenced volume-of-distribution and clearance, respectively. The half-life of baricitinib in patients less than 40?kg was substantially shorter than in adult populations, requiring the need for dosing up to 4 times daily. On therapeutic doses, the mean area-under-the-concentration-vs.-time curve was 2,388?nM*hr, which is 1.83-fold higher than mean baricitinib exposures in adult patients with rheumatoid arthritis receiving doses of 4?mg once-daily. Dose-dependent decreases in interferon (IFN) biomarkers confirmed an in vivo effect of baricitinib on type-1 IFN signaling. PopPK and pharmacodynamic data support a proposal for a weight- and estimated glomerular filtration rate-based dosing regimen in guiding baricitinib dosing in patients with rare interferonopathies.

SUBMITTER: Kim H 

PROVIDER: S-EPMC6089664 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.

Kim Hanna H   Brooks Kristina M KM   Tang Cheng Cai CC   Wakim Paul P   Blake Mary M   Brooks Stephen R SR   Montealegre Sanchez Gina A GA   de Jesus Adriana A AA   Huang Yan Y   Tsai Wanxia Li WL   Gadina Massimo M   Prakash Apurva A   Janes Jonathan Marcus JM   Zhang Xin X   Macias William L WL   Kumar Parag P   Goldbach-Mansky Raphaela R  

Clinical pharmacology and therapeutics 20171208 2


Population pharmacokinetic (popPK) modeling was used to characterize the PK profile of the oral Janus kinase (JAK)1/JAK2 inhibitor, baricitinib, in 18 patients with Mendelian interferonopathies who are enrolled in a compassionate use program. Patients received doses between 0.1 to 17 mg per day. Covariates of weight and renal function significantly influenced volume-of-distribution and clearance, respectively. The half-life of baricitinib in patients less than 40 kg was substantially shorter tha  ...[more]

Similar Datasets

| S-EPMC5563343 | biostudies-literature
| S-EPMC6212720 | biostudies-literature
| S-EPMC5094849 | biostudies-literature
| S-EPMC10196163 | biostudies-literature
| S-EPMC3088186 | biostudies-other
| S-EPMC6904296 | biostudies-literature
| S-EPMC8401444 | biostudies-literature
| S-EPMC4546409 | biostudies-literature
| S-EPMC6256001 | biostudies-literature
| S-EPMC7848983 | biostudies-literature